Genmab — November 2019
-
Portionen på de 10.000 i 1.500 røg i en mundfuld.
-
you can expect to see more partnerships, strategic partnerships of the company where we would potentially also spend more and more capital on. We also watching the landscape very, very carefully for next-generation technologies, which we think would complement our technology base, Emily. And of course, with the cash now on the bank, we actually -- we can actually move very swiftly and very quickly to actually broaden the technology base of the company, both product-wise and technology-wise.
-
And of course, with the cash now on the bank, we actually -- we can actually move very swiftly and very quickly to actually broaden the technology base of the company, both product-wise and technology-wise. And you'll see examples of each one of those in the coming time, I believe.
-
Ved ikke helt hvordan Jans svar skal forståes, for det kan også være produkt teknologi - eksempelvis ADC teknologi eller alm antistof teknologi......eller en helt ny teknologi til nye produkter ! Ville dog hellere have en aftale på et af Genmabs produkter, men det tror jeg ikke bliver i år
-
CEPHEUS seems fully recruited https://clinicaltrials.gov/ct2/history/NCT03652064?A=15&B=16&C=merged#StudyPageTop . They moved forward the Primary Completion date by 3,5 years, not sure why that is? Seems recruited rather fast
-
Artikel fra juni om J&J og Genmab.
https://www.fiercebiotech.com/biotech/j-j-bags-150m-option-genmab-s-darzalex-successor
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind